NexHA™ (hyaluronate sodium) Injectable Solution returns to market

Generic hyaluronic acid injection for horses now available for first time since 2015

FORT WORTH, TEXAS (March 4, 2024) – Vetoquinol announces that NexHA™ (hyaluronate sodium) Injectable Solution is now available for purchase. The product returns to the market with FDA approval for the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

“We are excited to let veterinarians and horse owners know that NexHA is back!” said Eric M. Alsup, DVM, General Manager, Vetoquinol USA. “Using affordable generics allows owners to put more money toward other important veterinary services without compromising standards of care.”

NexHA is an FDA-approved generic bioequivalent to Legend^®. Vetoquinol acquired NexHA as part of its purchase of Bioniche Animal Health in 2014. A prescription-only product, veterinarians can order NexHA from their Vetoquinol Territory Manager or preferred distributor representative.

About Vetoquinol USA

Headquartered in Fort Worth, Texas, Vetoquinol USA is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of AAFCO, NASC, EPA, and FDA-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.

NexHA™ (hyaluronate sodium) Injectable Solution is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.

IMPORTANT SAFETY INFORMATION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For use only in horses. Do not use in horses intended for human consumption.

NexHA™ (hyaluronate sodium) Injectable Solution 4 mL is approved only for intravenous use.

The safety of NexHA™ (hyaluronate sodium) Injectable Solution has not been evaluated in breeding stallions or in breeding, pregnant or lactating mares. Not for use in humans. Keep this and all other drugs out of reach of children. Post-Approval Experience: While all adverse reactions are not reported, the following adverse reactions are based on voluntary post-approval reporting for hyaluronate sodium injectable solution: Occasional depression, lethargy and fever. For full prescribing information, visit www.vetoquinolusa.com/nexha-info.

For media requests:
usa_news@vetoquinol.com

For customer requests:
Contact Vetoquinol
817-529-7500

©2024 Vetoquinol USA, Inc. Vetoquinol and NexHA are trademarks of Vetoquinol. Other brands are trademarks of their respective owners.